Sign up for free newsletter

 

DNA

IBS Capital sells IQuum stake to Roche

Tue, 17/06/2014 - 11:41

IBS Capital has sold its equity investment in IQuum to Roche. 

IBS made its initial capital investment in IQuum in 1999 shortly after the firm was founded and has remained its largest outside investor over the past 15 years. 
 
David Taft, the president of IBS, also served as a director on IQuum's board of directors since 1999.  During this period, IQuum developed groundbreaking technology in molecular diagnostics. 
 
Taft says: "IQuum's Laboratory-in-a-tube (Liat) System will dramatically improve the point of care segment of the diagnostics market and will bring significant benefits to Roche.  In combination with Roche's extensive technological, marketing and financial resources, the Liat system will provide healthcare clinics and hospitals with fast, accurate and simple to use testing for a wide range of medical conditions."


Subscribe to free daily newsletter
latestjobs
Fixed Income Dealer, London

Wed, 04 Mar 2015 00:00:00 GMT

SQL Developer

Wed, 04 Mar 2015 00:00:00 GMT

IT Project Manager – Global Markets

Wed, 04 Mar 2015 00:00:00 GMT

events
13 hours 53 min from now - London
13 hours 53 min from now - San Francisco
4 days 13 hours from now - Boston
specialreports